Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Jacques Raphael"'
Publikováno v:
Current Oncology, Vol 31, Iss 7, Pp 3682-3689 (2024)
Small-cell lung cancer (SCLC) remains a disease with poor prognosis, particularly in extensive-stage SCLC (ES-SCLC). Current standard-of-care treatment includes chemotherapy with platinum agents and etoposide plus immunotherapy with atezolizumab or d
Externí odkaz:
https://doaj.org/article/06dbcd3087724983ba1fbabe860adb91
Autor:
Ricardo Fernandes, Terry L. Ng, Mashari Jemaan Alzahrani, Jacques Raphael, Phillip Blanchette, Morgan Black, Carol Stober, Gregory R. Pond, David Cella, Lisa Vandermeer, Mohammed Ibrahim, Mark Clemons
Publikováno v:
Current Oncology, Vol 30, Iss 8, Pp 7384-7397 (2023)
Background: Neither paclitaxel plus trastuzumab (P-H) nor docetaxel-cyclophosphamide plus trastuzumab (TC-H) have been prospectively compared in HER2-positive early-stage breast cancer (EBC). A randomized trial was performed to assess the feasibility
Externí odkaz:
https://doaj.org/article/c4a34249d38c4c15b7d83418937e50a6
Publikováno v:
Current Oncology, Vol 30, Iss 4, Pp 4329-4350 (2023)
Antibody-Drug conjugates (ADCs) are a relatively new class of drugs with a promise to improve the outcomes in specific cancers. By delivering the cytotoxic agent to tumor cells expressing specific antigens, ADCs achieve a better therapeutic index and
Externí odkaz:
https://doaj.org/article/568a551acc004fdc80015db9bdc36a9e
Autor:
Richard A. Malthaner, Edward Yu, Michael Sanatani, Debra Lewis, Andrew Warner, A. Rashid Dar, Brian P. Yaremko, Joel Bierer, David A. Palma, Dalilah Fortin, Richard I. Inculet, Eric Fréchette, Jacques Raphael, Stewart Gaede, Sara Kuruvilla, Jawaid Younus, Mark D. Vincent, George B. Rodrigues
Publikováno v:
Thoracic Cancer, Vol 13, Iss 13, Pp 1898-1915 (2022)
Abstract Background We compared the health‐related quality of life (HRQOL) in patients undergoing trimodality therapy for resectable stage I‐III esophageal cancer. Methods A total of 96 patients were randomized to standard neoadjuvant cisplatin a
Externí odkaz:
https://doaj.org/article/3b12890c920c426ab850df2b1fe0356a
Autor:
Edward Yu, Alison L. Allan, Michael Sanatani, Debra Lewis, Andrew Warner, A. Rashid Dar, Brian P. Yaremko, Lori E. Lowes, David A. Palma, Jacques Raphael, Mark D. Vincent, George B. Rodrigues, Dalilah Fortin, Richard I. Inculet, Eric Frechette, Joel Bierer, Jeffery Law, Jawaid Younus, Richard A. Malthaner
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy. Methods We prospectively collected CTC data from pat
Externí odkaz:
https://doaj.org/article/8cb2db1ff05644bd83701d5be8c74a0a
Autor:
Phillip S. Blanchette, Melody Lam, Britney Le, Lucie Richard, Salimah Z. Shariff, Alexandra M. Ouédraogo, Kathleen I. Pritchard, Jacques Raphael, Ted Vandenberg, Ricardo Fernandes, Danielle N. Desautels, Kelvin K.W. Chan, Craig C. Earle
Publikováno v:
Breast, Vol 60, Iss , Pp 295-301 (2021)
Background: The use of endocrine therapy for early-stage breast cancer, particularly aromatase inhibitor therapy has been associated with an increased risk of osteoporosis and fracture in clinical trials. We sought to validate this observation in rea
Externí odkaz:
https://doaj.org/article/669ad70f8697435b982217ebf83fd6ed
Autor:
Paul Stewart, Phillip Blanchette, Prakesh S. Shah, Xiang Y. Ye, R. Gabriel Boldt, Ricardo Fernandes, Ted Vandenberg, Jacques Raphael
Publikováno v:
Breast, Vol 54, Iss , Pp 203-210 (2020)
One year of adjuvant trastuzumab is considered the standard treatment for patients with HER2 positive breast cancer. However, a shorter duration of trastuzumab may be associated with reduced costs and side effects. Results from randomized trials with
Externí odkaz:
https://doaj.org/article/9cbde4b7e15147f2803f3810968ad4ea
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
American Journal of Clinical Oncology. 46:87-93
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f71f6fb66ff50eb3a6e625f400747dfb
https://doi.org/10.1097/coc.0000000000000976
https://doi.org/10.1097/coc.0000000000000976
Autor:
Jacques Raphael, Lucie Richard, Melody Lam, Phillip Blanchette, Natasha B Leighl, George Rodrigues, Maureen Trudeau, Monika K Krzyzanowska
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background We sought to estimate the proportion of patients with cancer treated with immune checkpoint inhibitors (ICI) who die soon after starting ICI in the real world and to examine factors associated with early mortality (EM). Methods We conducte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54569cb238cff8bf0c2dddbf8c4a8c6f
https://doi.org/10.1093/jnci/djad090
https://doi.org/10.1093/jnci/djad090